Literature DB >> 12004249

Neutrophil elastase and acute lung injury: prospects for sivelestat and other neutrophil elastase inhibitors as therapeutics.

Bernhardt G Zeiher1, Shozo Matsuoka, Kazuhito Kawabata, John E Repine.   

Abstract

OBJECTIVES: To review the evidence and rationale that suggest that neutrophil elastase (NE) may contribute to the development of acute lung injury (ALI) and the acute respiratory distress syndrome. To review selected preliminary data regarding the effectiveness of NE inhibition in animals, in in vitro models, and in patients with ALI. DATA SOURCES: The published literature and observations provided by Ono Pharmaceutical and Eli Lilly investigators and their colleagues. DATA
SUMMARY: Taken en toto, the data suggest that NE could contribute to ALI and endothelial cell injury that is relevant to ALI. Moreover, the toxic effects of NE are greatly enhanced by increased oxidative stress, which commonly occurs in patients with ALI. In addition to neutrophils, xanthine oxidase, a constituent of endothelial cells, is a potential source of oxidative stress in ALI; xanthine oxidase-derived oxidants enhance NE toxicity in in vivo, isolated lung, and in vitro endothelial cell test systems. Not surprisingly, endogenous nonoxidatively sensitive NE inhibitors (e.g., eglin C) are more effective in combating the detrimental effects of NE than oxidatively sensitive NE inhibitors (e.g., alpha-1-proteinase inhibitor). In addition, a synthetic NE inhibitor, sivelestat (ONO-5046 and LY544349), is effective in reducing measures of inflammation and injury in multiple animal models of ALI. In a trial of ALI patients with systemic inflammatory response syndrome, conducted in Japan by Ono Pharmaceutical scientists, sivelestat treatment improved the investigator assessment of global improvement and the percentages of patients who were removed from ventilators and transferred out of the intensive care unit.
CONCLUSIONS: Further study of the role of NE inhibition as a treatment for ALI is warranted. Additional clinical and preclinical studies with sivelestat and various other NE inhibitors should not only clarify the clinical potential of this intervention strategy, but also better define the activities of NE in inflammatory disorders such as ALI and multiple organ failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12004249     DOI: 10.1097/00003246-200205001-00018

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  33 in total

1.  Effect of Ono-EI-600 elastase inhibitor on high-tidal-volume-induced lung injury in rats.

Authors:  Yasuki Fujita; Yuji Fujino; Yoshiko Maeda; Akinori Uchiyama; Takashi Mashimo; Masaji Nishimura
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

Review 2.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Usefulness of sivelestat sodium administration in patients with aspiration pneumonia.

Authors:  Toshihiro Kikuchi; Toyoki Kugimiya; Shinobu Katashima
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

4.  Inhibition of neutrophil elastase contributes to attenuation of lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice.

Authors:  Jong Min Lee; Chang Dong Yeo; Hwa Young Lee; Chin Kook Rhee; In Kyoung Kim; Dong Gun Lee; Sang Haak Lee; Jin Woo Kim
Journal:  J Anesth       Date:  2017-01-31       Impact factor: 2.078

5.  Suppressive effects of sivelestat on interleukin 8 and TNF-α production from LPS-stimulated granulocytes in whole blood culture.

Authors:  Shigehiro Shibata; Gaku Takahashi; Nobuki Shioya; Katsuya Inada; Shigeatsu Endo
Journal:  J Anesth       Date:  2010-10-26       Impact factor: 2.078

Review 6.  The role of neutrophils in the immune system: an overview.

Authors:  Harry L Malech; Frank R Deleo; Mark T Quinn
Journal:  Methods Mol Biol       Date:  2014

7.  Fluconazole attenuates lung injury and mortality in a rat peritonitis model.

Authors:  Mohammad Tariq; Ahmed Al Moutaery; Mohammed Arshaduddin; Haseeb Ahmad Khan; David Price Evans; Sydney Jacobs
Journal:  Intensive Care Med       Date:  2003-09-27       Impact factor: 17.440

8.  Neutrophil elastase mediates acute pathogenesis and is a determinant of long-term behavioral recovery after traumatic injury to the immature brain.

Authors:  Bridgette D Semple; Alpa Trivedi; Kayleen Gimlin; Linda J Noble-Haeusslein
Journal:  Neurobiol Dis       Date:  2014-12-09       Impact factor: 5.996

9.  Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function.

Authors:  Kevin M Vannella; Tracy R McMillan; Ryan P Charbeneau; Carol A Wilke; Peedikayil E Thomas; Galen B Toews; Marc Peters-Golden; Bethany B Moore
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

Review 10.  Therapy for chronic obstructive pulmonary disease in the 21st century.

Authors:  Louise E Donnelly; Duncan F Rogers
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.